When an embarrassment of riches isn’t enough: HAEMATOLOGICAL CANCER

Data on a new treatment approach utilizing bispecific monoclonal antibodies targetting B-cell maturation antigen (BCMA) were recently published, yielding very encouraging results in the setting of relapsed and/or refractory multiple myeloma (RRMM). How to safely and effectively deliver this treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Clinical oncology 2022, Vol.19 (10), p.617-618
Main Authors: Patel, Krina, Lonial, Sagar
Format: Article
Language:English
Subjects:
631/154/51
692/4028/67/1059/2325
692/4028/67/1059/2326
692/4028/67/1059/602
692/4028/67/1990/804
Medicine
Medicine & Public Health
News & Views
news-and-views
Oncology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data on a new treatment approach utilizing bispecific monoclonal antibodies targetting B-cell maturation antigen (BCMA) were recently published, yielding very encouraging results in the setting of relapsed and/or refractory multiple myeloma (RRMM). How to safely and effectively deliver this treatment to patients and where it fits in the RRMM treatment paradigm are important questions for the future.
ISSN:1759-4774
1759-4782
DOI:10.1038/s41571-022-00670-w